This finding aligns with a novel treatment approach that combines the anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab with pembrolizumab to enhance safety and efficacy in treating extensive-stage lung cancer.62 The gene discussed is CTLA4; the disease is lung cancer.